New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is one rare but clinically aggressive hematological malignancy, and it is typically characterized by skin lesion and bone marrow involvement. Diagnosis of BPDCN relies on the immunophenotype positive for four of CD4, CD56, CD123, TCL1 and BDCA-2,...
Gespeichert in:
| Veröffentlicht in: | Critical reviews in oncology/hematology 2020-05, Vol.149, p.102928-102928, Article 102928 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102928 |
|---|---|
| container_issue | |
| container_start_page | 102928 |
| container_title | Critical reviews in oncology/hematology |
| container_volume | 149 |
| creator | Zhang, Xiang Sun, Jiewen Yang, Min Wang, Lei Jin, Jie |
| description | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is one rare but clinically aggressive hematological malignancy, and it is typically characterized by skin lesion and bone marrow involvement. Diagnosis of BPDCN relies on the immunophenotype positive for four of CD4, CD56, CD123, TCL1 and BDCA-2, and commonly without the expression of MPO, cytoplasmic CD3, CD13, CD64, cytoplasmic CD79a, CD19 and CD20. Commonly, BPDCN is characterized by high CD123 expression, aberrant NF-κB activation, dependence on TCF4-/BRD4-network, and deregulated cholesterol metabolism. Under conventional therapy, the survival duration is only improved in a small number of BPDCN patients. Therefore, targeted therapy should be developed. Up to now, tagraxofusp is the leading edge and has been approved for BPDCN treatment. However, most of other targeted therapy agents were still not pushed to clinical trials for BPDCN. In this review, we emphatically discuss recent perspectives on BPDCN genetic features and developments of its targeted therapy. |
| doi_str_mv | 10.1016/j.critrevonc.2020.102928 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2385725961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842820300664</els_id><sourcerecordid>2385725961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-8aa0dd22cff35296b0fbb3f714428858cf95d1656c2f1e7cd97d8c7bfad4d38b3</originalsourceid><addsrcrecordid>eNqFkE1PwzAMhiMEYmPwF1COXDqSNG3TI0x8SRNc4ByliTMydW1JuqH9e1I64MjJlv3afv0ghCmZU0Lz6_Vce9d72LWNnjPChjIrmThCUyqKMiE8p8cxJ5wkgjMxQWchrAkhnOfFKZqkjKU8F2yKqmf4xB340IHu3Q4Cdg1eQQO90wGrxuBe-RX0EJN38KrbY9t6XNUqRAXuYtwove9bZ7CBxkRbsayhrnED7Xf7HJ1YVQe4OMQZeru_e108JsuXh6fFzTLRacH7RChFjGFMW5tmrMwrYqsqtQXl8QGRCW3LzNA8yzWzFAptysIIXVRWGW5SUaUzdDXu7Xz7sYXQy40LgxMVnWyDZKnICpaVOY1SMUq1b0PwYGXn3Ub5vaREDoTlWv4RlgNhORKOo5eHK9tqA-Z38AdpFNyOAoi_7hx4GbSDRoNxPjKWpnX_X_kCXNeUeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2385725961</pqid></control><display><type>article</type><title>New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zhang, Xiang ; Sun, Jiewen ; Yang, Min ; Wang, Lei ; Jin, Jie</creator><creatorcontrib>Zhang, Xiang ; Sun, Jiewen ; Yang, Min ; Wang, Lei ; Jin, Jie</creatorcontrib><description>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is one rare but clinically aggressive hematological malignancy, and it is typically characterized by skin lesion and bone marrow involvement. Diagnosis of BPDCN relies on the immunophenotype positive for four of CD4, CD56, CD123, TCL1 and BDCA-2, and commonly without the expression of MPO, cytoplasmic CD3, CD13, CD64, cytoplasmic CD79a, CD19 and CD20. Commonly, BPDCN is characterized by high CD123 expression, aberrant NF-κB activation, dependence on TCF4-/BRD4-network, and deregulated cholesterol metabolism. Under conventional therapy, the survival duration is only improved in a small number of BPDCN patients. Therefore, targeted therapy should be developed. Up to now, tagraxofusp is the leading edge and has been approved for BPDCN treatment. However, most of other targeted therapy agents were still not pushed to clinical trials for BPDCN. In this review, we emphatically discuss recent perspectives on BPDCN genetic features and developments of its targeted therapy.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2020.102928</identifier><identifier>PMID: 32234682</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Blastic plasmacytoid dendritic cell neoplasm ; Cell Cycle Proteins ; Dendritic Cells - pathology ; Genetics ; Hematologic Neoplasms - genetics ; Hematologic Neoplasms - pathology ; Hematologic Neoplasms - therapy ; Humans ; Molecular Targeted Therapy ; Nuclear Proteins ; Skin Neoplasms ; Targeted therapy ; Transcription Factors</subject><ispartof>Critical reviews in oncology/hematology, 2020-05, Vol.149, p.102928-102928, Article 102928</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-8aa0dd22cff35296b0fbb3f714428858cf95d1656c2f1e7cd97d8c7bfad4d38b3</citedby><cites>FETCH-LOGICAL-c374t-8aa0dd22cff35296b0fbb3f714428858cf95d1656c2f1e7cd97d8c7bfad4d38b3</cites><orcidid>0000-0002-8166-9915 ; 0000-0002-7543-8352</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.critrevonc.2020.102928$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32234682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Sun, Jiewen</creatorcontrib><creatorcontrib>Yang, Min</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Jin, Jie</creatorcontrib><title>New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is one rare but clinically aggressive hematological malignancy, and it is typically characterized by skin lesion and bone marrow involvement. Diagnosis of BPDCN relies on the immunophenotype positive for four of CD4, CD56, CD123, TCL1 and BDCA-2, and commonly without the expression of MPO, cytoplasmic CD3, CD13, CD64, cytoplasmic CD79a, CD19 and CD20. Commonly, BPDCN is characterized by high CD123 expression, aberrant NF-κB activation, dependence on TCF4-/BRD4-network, and deregulated cholesterol metabolism. Under conventional therapy, the survival duration is only improved in a small number of BPDCN patients. Therefore, targeted therapy should be developed. Up to now, tagraxofusp is the leading edge and has been approved for BPDCN treatment. However, most of other targeted therapy agents were still not pushed to clinical trials for BPDCN. In this review, we emphatically discuss recent perspectives on BPDCN genetic features and developments of its targeted therapy.</description><subject>Blastic plasmacytoid dendritic cell neoplasm</subject><subject>Cell Cycle Proteins</subject><subject>Dendritic Cells - pathology</subject><subject>Genetics</subject><subject>Hematologic Neoplasms - genetics</subject><subject>Hematologic Neoplasms - pathology</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Humans</subject><subject>Molecular Targeted Therapy</subject><subject>Nuclear Proteins</subject><subject>Skin Neoplasms</subject><subject>Targeted therapy</subject><subject>Transcription Factors</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1PwzAMhiMEYmPwF1COXDqSNG3TI0x8SRNc4ByliTMydW1JuqH9e1I64MjJlv3afv0ghCmZU0Lz6_Vce9d72LWNnjPChjIrmThCUyqKMiE8p8cxJ5wkgjMxQWchrAkhnOfFKZqkjKU8F2yKqmf4xB340IHu3Q4Cdg1eQQO90wGrxuBe-RX0EJN38KrbY9t6XNUqRAXuYtwove9bZ7CBxkRbsayhrnED7Xf7HJ1YVQe4OMQZeru_e108JsuXh6fFzTLRacH7RChFjGFMW5tmrMwrYqsqtQXl8QGRCW3LzNA8yzWzFAptysIIXVRWGW5SUaUzdDXu7Xz7sYXQy40LgxMVnWyDZKnICpaVOY1SMUq1b0PwYGXn3Ub5vaREDoTlWv4RlgNhORKOo5eHK9tqA-Z38AdpFNyOAoi_7hx4GbSDRoNxPjKWpnX_X_kCXNeUeQ</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Zhang, Xiang</creator><creator>Sun, Jiewen</creator><creator>Yang, Min</creator><creator>Wang, Lei</creator><creator>Jin, Jie</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8166-9915</orcidid><orcidid>https://orcid.org/0000-0002-7543-8352</orcidid></search><sort><creationdate>202005</creationdate><title>New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm</title><author>Zhang, Xiang ; Sun, Jiewen ; Yang, Min ; Wang, Lei ; Jin, Jie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-8aa0dd22cff35296b0fbb3f714428858cf95d1656c2f1e7cd97d8c7bfad4d38b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Blastic plasmacytoid dendritic cell neoplasm</topic><topic>Cell Cycle Proteins</topic><topic>Dendritic Cells - pathology</topic><topic>Genetics</topic><topic>Hematologic Neoplasms - genetics</topic><topic>Hematologic Neoplasms - pathology</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Humans</topic><topic>Molecular Targeted Therapy</topic><topic>Nuclear Proteins</topic><topic>Skin Neoplasms</topic><topic>Targeted therapy</topic><topic>Transcription Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Sun, Jiewen</creatorcontrib><creatorcontrib>Yang, Min</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Jin, Jie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xiang</au><au>Sun, Jiewen</au><au>Yang, Min</au><au>Wang, Lei</au><au>Jin, Jie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2020-05</date><risdate>2020</risdate><volume>149</volume><spage>102928</spage><epage>102928</epage><pages>102928-102928</pages><artnum>102928</artnum><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is one rare but clinically aggressive hematological malignancy, and it is typically characterized by skin lesion and bone marrow involvement. Diagnosis of BPDCN relies on the immunophenotype positive for four of CD4, CD56, CD123, TCL1 and BDCA-2, and commonly without the expression of MPO, cytoplasmic CD3, CD13, CD64, cytoplasmic CD79a, CD19 and CD20. Commonly, BPDCN is characterized by high CD123 expression, aberrant NF-κB activation, dependence on TCF4-/BRD4-network, and deregulated cholesterol metabolism. Under conventional therapy, the survival duration is only improved in a small number of BPDCN patients. Therefore, targeted therapy should be developed. Up to now, tagraxofusp is the leading edge and has been approved for BPDCN treatment. However, most of other targeted therapy agents were still not pushed to clinical trials for BPDCN. In this review, we emphatically discuss recent perspectives on BPDCN genetic features and developments of its targeted therapy.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32234682</pmid><doi>10.1016/j.critrevonc.2020.102928</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8166-9915</orcidid><orcidid>https://orcid.org/0000-0002-7543-8352</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8428 |
| ispartof | Critical reviews in oncology/hematology, 2020-05, Vol.149, p.102928-102928, Article 102928 |
| issn | 1040-8428 1879-0461 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2385725961 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Blastic plasmacytoid dendritic cell neoplasm Cell Cycle Proteins Dendritic Cells - pathology Genetics Hematologic Neoplasms - genetics Hematologic Neoplasms - pathology Hematologic Neoplasms - therapy Humans Molecular Targeted Therapy Nuclear Proteins Skin Neoplasms Targeted therapy Transcription Factors |
| title | New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T00%3A01%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20perspectives%20in%20genetics%20and%20targeted%20therapy%20for%20blastic%20plasmacytoid%20dendritic%20cell%20neoplasm&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Zhang,%20Xiang&rft.date=2020-05&rft.volume=149&rft.spage=102928&rft.epage=102928&rft.pages=102928-102928&rft.artnum=102928&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2020.102928&rft_dat=%3Cproquest_cross%3E2385725961%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2385725961&rft_id=info:pmid/32234682&rft_els_id=S1040842820300664&rfr_iscdi=true |